lundi 11 décembre 2017

Onco Actu du 11 décembre 2017

2. Etiologie

Gum infections tied to increased risk of stomach cancer precursor [Reuters]

2.8 Etiologie - Contraceptifs, THS

Birth control pills & breast cancer risk: big study generates big differences in quality of news coverage [HealthNewsReview]

The New Health Care: Birth Control and Breast Cancer: Look Beyond the Headlines [NY Times]

4. Dépistage, diagnostic et pronostic

Does Cancer Screening Save More Lives Overall? Not Necessarily [WBUR]

4.1 Dép., diag. & prono. - Prostate

Common Genetic Fusion Event May be Associated with Low-risk Prostate Cancer [AACR]

4.9 Dép., diag. & prono. - Sein

Breast cancer screening – is it worth it? [The Guardian]

It's Time to End Mammograms, Some Experts Say [TIME]

5.12 Immunothérapies

With Advances in Cancer Immunotherapy, Scientists Discuss Need to Develop New Mouse Models [NCI]

5.12.1 Immunothérapies - partenariats

bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy [bluebird bio]

Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm’s tumor invading tech platform [EndPoints]

5.12.2 Immunothérapies - CAR-T

Genetic Programmers Are the Next Startup Millionaires [MIT Technology Review]

5.12.5 Immunothérapies - Pharma

Roche Tecentriq combo effective, but is it enough? [Pharmafile]

Roche: Tecentriq cocktail slows kidney cancer progression [Reuters]

Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer [Roche]

Merck raises stakes in lung cancer as rivals close in [Reuters]

5.12.8 Immunothérapies - Economie

Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs [EndPoints]

5.2 Pharma

Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer [Lilly]

AstraZeneca and GSK start fightback after big year for blood cancer treatments [The Telegraph]

Lilly's stomach cancer drug meets main goal, but fails to improve survival rate [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

M&A slows to a trickle in 2017, but Big Pharma could be on deck for mega deals [EndPoints]

5.4 Traitements - Economie

New deal will give people with kidney cancer another treatment option [NICE]

A Cancer-Drug Pricing Experiment Just Got More Interesting [Bloomberg]

5.6 ESMO

ESMO IO 2017 Press Release: Novel Compound Restores Immune Response In Patients With Melanoma [ESMO]

ESMO IO 2017 Press Release: Researchers Discover Resistance Mechanism To Checkpoint Inhibitors And How To Reverse It [ESMO]

Roche study finds cancer 'Velcro' that halts T-cell attack [Reuters]


Phase III Trial Data Support Current Standard 12-month Adjuvant Trastuzumab for HER2-positive Breast Cancer [AACR]

Two Years of Extended Anastrozole Therapy Proved as Effective as Five Years in Clinical Trial [AACR]

In Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves Symptoms [Forbes]

5.7.2 SABCS-divers

Breast cancer less likely to come back with more intensive chemo [Cancer Research UK]


Temporary Ovarian Suppression With Hormone Analog May Preserve Fertility During Breast Cancer Chemotherapy [AACR]

Acupuncture Reduced Joint Pain Caused by Aromatase Inhibitor Treatment in a Randomized, Phase III Clinical Trial [AACR]

Lymph Node Surgery May Raise Risk of Arm Morbidity in Younger Women [AACR]

Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk [AACR]

Older Women with HR-positive Breast Cancer May Receive Similar Benefit from CDK 4/6 Inhibitors as Younger Women [AACR]

5.7.4 SABCS-essais

Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer [Pfizer]

Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported [Celgene]

Phase III EMBRACA Trial Meets Primary Endpoint [AACR]

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib [EndPoints]

Pfizer breast cancer drug superior to chemotherapy in late stage study [Reuters]

5.7.5 SABCS-biopsies liquides

Blood test may help predict which breast cancers will recur [STAT]

Circulating Tumor Cells May Predict Late Recurrence in HR-positive Breast Cancer Patients [AACR]

5.8.1 ASH - Communiqués

Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies [ASH]

5.8.3 ASH - Divers

Blueprint elbows its way to center ring with early data and a plan to seek quick FDA OK [EndPoints]

5.8.4 ASH - CAR T

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma [ASH]

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting [Celgene]

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer [Novartis]

The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight [EndPoints]

How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead? [EndPoints]

Novartis CAR-T therapy leads to durable response in lymphoma study [Reuters]

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study [Reuters]

A Milestone for CAR T Cells [NEJM]

Gilead's new drug keeps 56 percent of lymphoma trial patients alive [Reuters]

5.8.6 ASH - Leucémies

IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients [AbbVie]

5.8.7 ASH - Lymphomes

Seattle Genetics CEO Clay Siegall has an answer for the skeptics doubting Adcetris data for Hodgkin lymphoma [EndPoints]

IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) [AbbVie]

Roche unveils stellar PhII DLBCL data for one of its top hematology drugs in the pipeline [EndPoints]

Verastem’s AbbVie castoff is headed for the FDA — even after missing overall survival goal [EndPoints]

Roche lymphoma drug drives high remission rate, longer survival: study [Reuters]

Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma [Roche]

6.1 Observation

Childhood cancer survivors have more blood pressure problems [Reuters]

6.10 Politiques

Brexit agreement would allow EU scientists to stay in United Kingdom [Science]

6.10.1 Politiques (USA)

U.S. House committee 'may reconsider' WHO cancer agency funds [Reuters]

6.7.1 Bioinformatique

Google Is Giving Away AI That Can Build Your Genome Sequence [Wired]

A test drive of a DNA-analysis toolkit in the cloud [Nature]